Doc Logic, thanks for providing us with the percentages behind the Mesenchymal genotype that DCVasL is known to help the most and for explaining in plain language why the FDA needs to approve this treatment if we truly see significant extensions in life for nGBM as well as recurrent GBM at unblinding of the trial. I particularly appreciate learning that at progression about 85% of tumors express mesenchymal gene type (or is it phenotype as you wrote?) I knew that mesenchymal type is usually expressed when the disease metastasizes to other areas, but its well worth repeating....because it’s often those metastases that kill its victims.
Thanks Doc Logic that really makes sense. Common sense woulld say that when everyone is living longer that the treatment is working ...without side effects. Move it FDA!!
Wait until President Trump signs the Federal "Right to Try" Bill in a couple of weeks. The outpouring of people clambering all over the place to get DCVax will be unbelievable. I think you'll see the FDA will get their heads out of their asses really quick. The jig is up for those trying to kill this company